Developing new exosome-based treatments for aggressive breast cancer
Reprogramming Exosomes for Novel Immunotherapy of Triple Negative Breast Cancer
This study is exploring a new way to boost the immune system's ability to fight triple negative breast cancer by using specially designed tiny particles called exosomes, which could lead to better treatments for patients facing this tough type of cancer.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Southern California NIH-funded |
| Lab location | 1 site (Los Angeles, UNITED STATES) |
| Project ID | NIH-10899640 on NIH RePORTER |
What this research studies
This research focuses on creating engineered exosomes to enhance the immune response against triple negative breast cancer (TNBC), a particularly aggressive form of breast cancer. The project involves designing and characterizing these synthetic exosomes to activate specific antitumor immunity and induce immune responses targeting TNBC tumors. By understanding how these reprogrammed exosomes work, the research aims to develop a new class of immunotherapeutics that could be safely and effectively used in clinical settings.
Who could benefit from this research
Good fit: Ideal candidates for this research are patients diagnosed with triple negative breast cancer who have limited treatment options.
Not a fit: Patients with other subtypes of breast cancer or those who are not diagnosed with breast cancer may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could provide a novel and effective treatment option for patients with triple negative breast cancer.
How similar studies have performed: Other research has shown promise in using engineered exosomes for cancer treatment, indicating potential success for this novel approach.
Where this research is happening
Los Angeles, UNITED STATES
- University of Southern California — Los Angeles, United States (Active)
Researchers
- Principal investigator: Zhang, Yong — University of Southern California
- Study coordinator: Zhang, Yong
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.